Compare Pfizer Inc (PFE) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Rockwell Automation — how do they compare? Pfizer Inc trades at $27.8 (market cap $158.56B), while Rockwell Automation trades at $438.29 (market cap $48.21B). The key difference: Pfizer Inc is far larger — about 3.3× Rockwell Automation's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Rockwell Automation for 74 Days on average.
| PFE | ROK | |
|---|---|---|
Market Cap | $158.56B | $48.21B |
Volume | 44,138,282 | 953,342 |
Sector | Health | Industrials |
52-Week High | $29.02 | $495.08 |
52-Week Low | $23.67 | $333.75 |
Typical Hold Time | 158 Days | 74 Days |
Enterprise Value | $210.06B | $51.34B |
Dividend Yield | 6.18% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Rockwell Automation (ROK) trades at $441.9, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $489.89 implying 11% upside. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending, and maintains strong profitability with a 13.38% net income margin and 34.47% ROE. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms.
ROK presents a growth opportunity driven by automation demand and digital transformation trends, but faces risks from high valuation multiples (P/E 41.38) and cyclical industrial spending. Analyst sentiment is mixed with 68% hold ratings, reflecting caution amid solid fundamentals. Investors should weigh earnings consistency against premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
